Zhu Mingxin, Bian Yi, Jiang Jipin, Lei Ting, Shu Kai
Department of Neurosurgery.
Department of Emergency.
Medicine (Baltimore). 2020 Dec 4;99(49):e22808. doi: 10.1097/MD.0000000000022808.
With the increasing demand on organ transplants, it has become a common practice to include patients with primary central nervous system (CNS) malignancies as donors given the suggested low probability metastatic spread outside of the CNS. However, an extra-CNS spread of the disease cannot be excluded raising potential risks of cancer transmission from those donors. In order to balance between the risk of donor-derived disease transmission and the curative benefit for the recipient, a careful donor and organ selection is important. We performed a literature research and summarized all reported studies of organ transplants from donors suffered from primary CNS malignancies and determined the risk of tumor transmission to recipients. There were 22 cases of transplant-transmitted CNS tumors onto recipients since 1976. The association risks of cancer transmission were attributed to donor tumor histology, disruption of the blood-brain barrier, cerebrospinal fluid extra-CNS, and false diagnosis of primary intracranial tumor as well as the molecular properties of the primary tumor such as the existence of EGFR-amplification. The association risks and features of CNS tumors transmission recipients indicated that we need to reassess our thresholds for the potential fatal consequences of these donors.
随着对器官移植需求的不断增加,鉴于原发性中枢神经系统(CNS)恶性肿瘤患者被认为中枢神经系统外转移概率较低,将其作为供体已成为一种常见做法。然而,不能排除疾病的中枢神经系统外扩散,这增加了来自这些供体的癌症传播的潜在风险。为了在供体源性疾病传播风险与受体的治疗益处之间取得平衡,仔细选择供体和器官很重要。我们进行了文献研究,总结了所有关于来自原发性中枢神经系统恶性肿瘤供体的器官移植的报道研究,并确定了肿瘤传播给受体的风险。自1976年以来,有22例移植传播的中枢神经系统肿瘤到受体身上。癌症传播的关联风险归因于供体肿瘤组织学、血脑屏障破坏、脑脊液中枢神经系统外扩散、原发性颅内肿瘤的误诊以及原发性肿瘤的分子特性,如表皮生长因子受体(EGFR)扩增的存在。中枢神经系统肿瘤传播给受体的关联风险和特征表明,我们需要重新评估这些供体潜在致命后果的阈值。